Anti-mycobacterial activity of plumericin and isoplumericin against MDR Mycobacterium tuberculosis

Pulmonary Pharmacology and Therapeutics

Volumn 26, Issue 3, 2013, Pages 332-335

  Kumar, Parveen ^a   Singh, Amit ^a   Sharma, Umakant ^a   Singh, Dharmendra ^a   Dobhal, M P ^b   Singh, Sarman ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b UNIVERSITY OF RAJASTHAN   (India)

Author keywords

Isoplumericin; MDR; Plumericin; Tuberculosis

Indexed keywords

ANTIMYCOBACTERIAL AGENT; IRIDOID; ISONIAZID; ISOPLUMERICIN; PLUMERICIN; RIFAMPICIN; UNCLASSIFIED DRUG;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BARK; CYTOTOXICITY TEST; DRUG CYTOTOXICITY; DRUG ISOLATION; IN VITRO STUDY; MEDICINAL PLANT; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PLUMERIA BICOLOR; PRIORITY JOURNAL;

ANIMALS; ANTITUBERCULAR AGENTS; APOCYNACEAE; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INDENES; IRIDOIDS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; PLANT EXTRACTS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84875961105     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2013.01.003     Document Type: Article

References (25)

1. Revised National TB Control Programme. TB India 2011 RNTCP annual status report. Retrieved from. http://www.tbcindia.org/pdfs/RNTCP%20TB%20India%202011.pdf.
2. World Health Organisation. What is DOTS? A guide to understanding the WHO-recommended TB control strategy known as DOTS. Retrieved from. http://whqlibdoc.who.int/hq/1999/WHO_CDS_CPC_TB_99.270.pdf.
3. Molly F.F., Sasha C.A., Jaime B., Fernando A., Eda P., Karim L., et al. Risk factors and mortality associated with default from multidrug-resistant tuberculosis treatment. Clin Infect Dis 2008, 46:1844-1851.
4. Kumar N., Singh B., Kaul V.K., Ahuja P.S. Chemical and biological aspects of iridoid bearing plants of temperate region. Stud Nat Prod Chem 2005, 32:247-302.
5. Luna-Herrera J., Costa M.C., Gonzalez H.G., Rodrigues A.I., Castilho P.C. Synergistic antimycobacterial activities of sesquiterpene lactones from Laurus spp. J Antimicrob Chemother 2007, 59:548-552.
6. Gupta R.S., Bhatnager A.K., Joshi Y.C., Sharma R., Sharma A. Effects of plumieride, an iridoid on spermatogenesis in male albino rats. Phytomed 2004, 11:169-174.
7. Dobhal M.P., Li G., Gryshuk A., Graham A., Bhatanager A.K., Khaja S.D., et al. Structural modifications of plumieride isolated from Plumeria bicolor and the effect of these modifications on in vitro anticancer activity. J Org Chem 2004, 69:6165-6172.
8. Sharma U., Singh D., Kumar P., Dobhal M.P., Singh S. Antiparasitic activity of plumericin & isoplumericin isolated from Plumeria bicolor against Leishmania donovani. Indian J Med Res 2011, 34:709-716.
9. Singh D., Sharma U., Kumar P., Gupta Y.K., Dobhal M.P., Singh S. Antifungal activity of plumericin and isoplumericin. Nat Prod Commun 2011, 6:1567-1568.
10. Abdel-Kader M.S., Wisse J., Evans R., Vander W.H., Kingston D.G. Bioactive iridoids and a new lignan from Allamanda cathartica and Himatanthus fallax from the Suriname rainforest. J Nat Prod 1997, 60:1294-1297.
11. Wood C.A., Lee K., Vaisberg A.J., Kingston D.G.I., Neto C.C., Hammond G.B. A bioactive spirolactone iridoid and triterpenoids from Himatanthus sucuuba. Chem Pharm Bull 2001, 49:1477-1478.
12. Singh S., Sankar M.M., Gopinath K. High rate of extensively drug-resistant tuberculosis in Indian AIDS patients. AIDS 2007, 2:2345-2347.
13. Kent T.P., Kubica P.G. Public health mycobacteriology. A guide for the level III laboratory 1985, Centers for Disease Control, Atlanta, Georgia.
14. World Health Organisation. Non-commercial culture and drug-susceptibility testing methods for screening of patients at risk of multi drug resistant tuberculosis. Policy statement-2011. Retrieved from. http://whqlibdoc.who.int/publications/2011/9789241501620_eng.pdf.
15. Sankar M.M., Gopinath K., Singla R., Singh S. In-vitro antimycobacterial drug susceptibility testing of non-tubercular mycobacteria by tetrazolium microplate assay. Ann Clin Microbiol Antimicrob 2008, 7:7-15.
16. Hurdle J.G., Lee R.B., Budha N.R., Carson E.I., Qi J., Scherman M.S., et al. A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents. J Antimicrob Chemother 2008, 62:1037-1045.
17. Tiuman T.S., Ueda-Nakamura T., Cortez D.A.G., Filho B.P.D., Morgado-Diaz J.A., de Souza W., et al. Anti-leishmanial activity of parthenolide, a sesquiterpene lactone isolated from Tanacetum parthenium. Antimicrob Agents Chemother 2005, 49:176-182.
18. María R.C., Juan M.J.F., Omar G., Elvira G., Gloria M.M., Salvador S., et al. Evaluation of some plant-derived secondary metabolites against sensitive and multidrug-resistant Mycobacterium tuberculosis. J Mex Chem Soc 2009, 53:71-77.
19. Buwa L.V., Afolayan A.J. Antimicrobial activity of some medicinal plants used for the treatment of tuberculosis in the Eastern Cape Province, South Africa. Afri J Biotech 2009, 8:6683-6687.
20. Rasool S.N., Jaheerunnisa S., Chitta S.K., Jayaveera K.N. Antimicrobial activities of Plumeria acutifolia. J Med Plants Res 2008, 2:77-80.
21. Mack R.K., Hector R.M., David A., Scott F.S., Brian B.G., Mark M.S., et al. Targeting tuberculosis and malaria through inhibition of enoyl reductase. J Biol Chem 2003, 278:20851-20859.
22. Ineke V.D., Munier-Lehmann H., Matheus F., Jan B., Serge V.C. Rational design of 5'-thiourea-substituted α-thymidine analogues as thymidine monophosphate kinase inhibitors capable of inhibiting mycobacterial growth. J Med Chem 2007, 50:5281-5292.
23. Kupchan S.M., Giacobbe T.J., Krull J.S., Thomas A.M., Eakin M.A., Fessler D.C. Reaction of endocyclic α, β-unsaturated lactones with thiols. J Org Chem 1970, 35:3539-3543.
24. Trost B.M., Mao M.K.T., Balkovec J.M., Bulhmayer P. A total synthesis of plumericin, allamcin, and allamandin. Part 1 basic strategy. J Am Chem Soci 1986, 108:4965-4973.
25. World Health Organisation Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs 2008, Reterived from. http://whqlibdoc.who.int/hq/2008/WHO_HTM_TB_2008.392_eng.pdf.